InVision Medical Technology (YC S22) — AI diagnosis of heart disease
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians.
InVision Medical Technology is a Y Combinator company in the Summer 2022 batch. Its directory entry describes it as: AI Diagnosis of Heart Disease. The founders listed are David Ouyang (Founder), Bryan He (Founder) (Y Combinator directory entry, August 26, 2022).
Get an email when InVision Medical Technology changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with InVision Medical Technology?
Get the full cited report on InVision Medical Technology
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
David Ouyang
Founder
Bryan He
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on InVision Medical Technology?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on InVision Medical Technology: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InVision Medical Technology covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind InVision Medical Technology: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
InVision Medical Technology (YC S22) — AI diagnosis of heart disease. MentionFox, 2026-10-20. https://mentionfox.com/funding/yc-invision-medical-technology
